Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Chris J. O'Callaghan"'
Autor:
Jodi I. Rattner, Karen A. Kopciuk, Hans J. Vogel, Patricia A. Tang, Jeremy D. Shapiro, Dongsheng Tu, Derek J. Jonker, Lillian L. Siu, Chris J. O'Callaghan, Oliver F. Bathe
Publikováno v:
Cancer Medicine, Vol 12, Iss 15, Pp 16019-16031 (2023)
Abstract Background Trials of tyrosine kinase inhibitors (TKI) have not demonstrated dramatic benefits in advanced colorectal cancer (CRC), and this may be a function of poor patient selection. TKI‐induced hypertension is reportedly a surrogate mar
Externí odkaz:
https://doaj.org/article/2a1d6528235b407c91d1a1c8ef8b8cee
Autor:
Jiahui Zhang, Weili Kong, Pingzhao Hu, Derek Jonker, Malcolm Moore, Jolie Ringash, Jeremy Shapiro, John Zalcberg, John Simes, Dongsheng Tu, Chris J. O'Callaghan, Geoffrey Liu, Wei Xu
Publikováno v:
Cancer Medicine, Vol 12, Iss 5, Pp 6117-6128 (2023)
Abstract Introduction Analyzing longitudinal cancer quality‐of‐life (QoL) measurements and their impact on clinical outcomes may improve our understanding of patient trajectories during systemic therapy. We applied an unsupervised growth mixture
Externí odkaz:
https://doaj.org/article/e98604b9e01d429ab3224b63de1b5b33
Autor:
Mélina Boutin, James T. Topham, Harriet Feilotter, Hagen F. Kennecke, Félix Couture, Mohammed Harb, Peter Kavan, Scott Berry, Howard J. Lim, John R. Goffin, Chaudhary Ahmad, Anthony Lott, Daniel J. Renouf, Derek J. Jonker, Dongsheng Tu, Chris J. O’Callaghan, Eric X. Chen, Jonathan M. Loree
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: The number of somatic mutations detectable in circulating tumor DNA (ctDNA) is highly heterogeneous in metastatic colorectal cancer (mCRC). The optimal number of mutations required to assess disease kinetics is relevant and remains poorly
Externí odkaz:
https://doaj.org/article/e6eff85bf5f845bf871d3d8d86b0404b
Autor:
Daniel Shepshelovich, Amanda R. Townsend, Osvaldo Espin‐Garcia, Lidija Latifovic, Chris J. O’Callaghan, Derek J. Jonker, Dongsheng Tu, Eric Chen, Eric Morgen, Timothy J. Price, Jeremy Shapiro, Lillian L. Siu, Michiaki Kubo, Alexander Dobrovic, Mark J. Ratain, Wei Xu, Taisei Mushiroda, Geoffrey Liu
Publikováno v:
Cancer Medicine, Vol 7, Iss 11, Pp 5478-5487 (2018)
Abstract Background Two germ line Fc‐γ receptor (FCGR) polymorphisms, rs1801274 [FCGR2A; His(H)131Arg(R)] and rs396991 [FCGR3A; Phe(F)158Val(V)], produce altered proteins through amino acid substitutions. We previously reported that the FCGR2A H/H
Externí odkaz:
https://doaj.org/article/628a67c545864055ae4f182dd106b2be
Autor:
Daniel J. Renouf, Jonathan M. Loree, Jennifer J. Knox, James T. Topham, Petr Kavan, Derek Jonker, Stephen Welch, Felix Couture, Frederic Lemay, Mustapha Tehfe, Mohammed Harb, Nathalie Aucoin, Yoo-Joung Ko, Patricia A. Tang, Ravi Ramjeesingh, Brandon M. Meyers, Christina A. Kim, Pan Du, Shidong Jia, David F. Schaeffer, Sharlene Gill, Dongsheng Tu, Chris J O’Callaghan
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-8 (2022)
Metastatic pancreatic ductal adenocarcinoma (mPDAC) has limited therapeutic options and is associated with a poor prognosis. Here the authors report the results of a randomized phase II trial showing that combining checkpoint inhibitors (durvalumab a
Externí odkaz:
https://doaj.org/article/ccff0c483c6e49d4b8726cac04df8470
Autor:
Yangqing Deng, Dongsheng Tu, Chris J O'Callaghan, Derek J Jonker, Christos S Karapetis, Jeremy Shapiro, Geoffrey Liu, Wei Xu
Publikováno v:
Statistics in Medicine. 42:2241-2256
Autor:
James T. Topham, Chris J. O'Callaghan, Harriet Feilotter, Hagen F. Kennecke, Young S. Lee, Weimin Li, Kimberly C. Banks, Katie Quinn, Daniel J. Renouf, Derek J. Jonker, Dongsheng Tu, Eric X. Chen, Jonathan M. Loree
Publikováno v:
Journal of Clinical Oncology. 41:485-496
PURPOSE Anti–epidermal growth factor receptor (EGFR) antibodies are effective treatments for metastatic colorectal cancer. Improved understanding of acquired resistance mechanisms may facilitate circulating tumor DNA (ctDNA) monitoring, anti-EGFR r
Autor:
Scott Kopetz, Stanley R. Hamilton, Hagen F. Kennecke, Paul Waring, Chris J. O'Callaghan, Christos S. Karapetis, Malcolm J. Moore, John R. Zalcberg, Timothy Price, Frank Holtrup, Hannah Quinn, Daniel L. Edelstein, Derek J. Jonker, Dongsheng Tu, Anthony Dowers, Jonathan M. Loree
Supplemental Tables and Figure Caption
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5b2729e1f3b3fb50a9551f5cdff0d70
https://doi.org/10.1158/1078-0432.22478880.v1
https://doi.org/10.1158/1078-0432.22478880.v1
Autor:
Scott Kopetz, Stanley R. Hamilton, Hagen F. Kennecke, Paul Waring, Chris J. O'Callaghan, Christos S. Karapetis, Malcolm J. Moore, John R. Zalcberg, Timothy Price, Frank Holtrup, Hannah Quinn, Daniel L. Edelstein, Derek J. Jonker, Dongsheng Tu, Anthony Dowers, Jonathan M. Loree
Supplemental Figure 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::082a795b700a781b2bbf2ea351e1df63
https://doi.org/10.1158/1078-0432.22478883.v1
https://doi.org/10.1158/1078-0432.22478883.v1
Autor:
Scott Kopetz, Stanley R. Hamilton, Hagen F. Kennecke, Paul Waring, Chris J. O'Callaghan, Christos S. Karapetis, Malcolm J. Moore, John R. Zalcberg, Timothy Price, Frank Holtrup, Hannah Quinn, Daniel L. Edelstein, Derek J. Jonker, Dongsheng Tu, Anthony Dowers, Jonathan M. Loree
Purpose:Expanded RAS/BRAF mutations have not been assessed as predictive for single-agent cetuximab in metastatic colorectal cancer (mCRC), and low mutant allele frequency (MAF) mutations are of unclear significance. We aimed to establish cetuximab e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3493ab03c0ff06263423b1839a575e1e
https://doi.org/10.1158/1078-0432.c.6530073.v1
https://doi.org/10.1158/1078-0432.c.6530073.v1